News | April 12, 2024
CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)